166 related articles for article (PubMed ID: 32827494)
1. Do Phospholipids Boost or Attenuate Drug Absorption? In Vitro and In Vivo Evaluation of Mono- and Diacyl Phospholipid-Based Solid Dispersions of Celecoxib.
Jacobsen AC; Ejskjær L; Brandl M; Holm R; Bauer-Brandl A
J Pharm Sci; 2021 Jan; 110(1):198-207. PubMed ID: 32827494
[TBL] [Abstract][Full Text] [Related]
2. A dynamic in vitro permeation study on solid mono- and diacyl-phospholipid dispersions of celecoxib.
Jacobsen AC; Elvang PA; Bauer-Brandl A; Brandl M
Eur J Pharm Sci; 2019 Jan; 127():199-207. PubMed ID: 30408522
[TBL] [Abstract][Full Text] [Related]
3. Amorphous drug dispersions with mono- and diacyl lecithin: On molecular categorization of their feasibility and UV dissolution imaging.
Gautschi N; Van Hoogevest P; Kuentz M
Int J Pharm; 2015 Aug; 491(1-2):218-30. PubMed ID: 26129840
[TBL] [Abstract][Full Text] [Related]
4. Solid Phospholipid Dispersions for Oral Delivery of Poorly Soluble Drugs: Investigation Into Celecoxib Incorporation and Solubility-In Vitro Permeability Enhancement.
Fong SY; Martins SM; Brandl M; Bauer-Brandl A
J Pharm Sci; 2016 Mar; 105(3):1113-23. PubMed ID: 26886329
[TBL] [Abstract][Full Text] [Related]
5. Hydrogenated phospholipid, a promising excipient in amorphous solid dispersions of fenofibrate for oral delivery: Preparation and in-vitro biopharmaceutical characterization.
Czajkowski M; Jacobsen AC; Bauer-Brandl A; Brandl M; Skupin-Mrugalska P
Int J Pharm; 2023 Sep; 644():123294. PubMed ID: 37544387
[TBL] [Abstract][Full Text] [Related]
6. Exploring impact of supersaturated lipid-based drug delivery systems of celecoxib on in vitro permeation across Permeapad
Ilie AR; Griffin BT; Brandl M; Bauer-Brandl A; Jacobsen AC; Vertzoni M; Kuentz M; Kolakovic R; Holm R
Eur J Pharm Sci; 2020 Sep; 152():105452. PubMed ID: 32622980
[TBL] [Abstract][Full Text] [Related]
7. Molecular insights into the formation of drug-monoacyl phosphatidylcholine solid dispersions for oral delivery.
Gautschi N; Van Hoogevest P; Kuentz M
Eur J Pharm Sci; 2017 Oct; 108():93-100. PubMed ID: 27240778
[TBL] [Abstract][Full Text] [Related]
8. Toward simplified oral lipid-based drug delivery using mono-/di-glycerides as single component excipients.
Ilie AR; Griffin BT; Vertzoni M; Kuentz M; Cuyckens F; Wuyts K; Kolakovic R; Holm R
Drug Dev Ind Pharm; 2020 Dec; 46(12):2051-2060. PubMed ID: 33124918
[TBL] [Abstract][Full Text] [Related]
9. Using in vitro lipolysis and SPECT/CT in vivo imaging to understand oral absorption of fenofibrate from lipid-based drug delivery systems.
Tran T; Bønløkke P; Rodríguez-Rodríguez C; Nosrati Z; Esquinas PL; Borkar N; Plum J; Strindberg S; Karagiozov S; Rades T; Müllertz A; Saatchi K; Häfeli UO
J Control Release; 2020 Jan; 317():375-384. PubMed ID: 31765705
[TBL] [Abstract][Full Text] [Related]
10. Novel lipid-based formulations enhancing the in vitro dissolution and permeability characteristics of a poorly water-soluble model drug, piroxicam.
Prabhu S; Ortega M; Ma C
Int J Pharm; 2005 Sep; 301(1-2):209-16. PubMed ID: 16046087
[TBL] [Abstract][Full Text] [Related]
11. Amorphous solid dispersion of berberine with absorption enhancer demonstrates a remarkable hypoglycemic effect via improving its bioavailability.
Zhaojie M; Ming Z; Shengnan W; Xiaojia B; Hatch GM; Jingkai G; Li C
Int J Pharm; 2014 Jun; 467(1-2):50-9. PubMed ID: 24607213
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
Fei Y; Kostewicz ES; Sheu MT; Dressman JB
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
[TBL] [Abstract][Full Text] [Related]
13. Effects of Lipid Digestion and Drug Permeation/Re-Dissolution on Absorption of Orally Administered Ritonavir as Different Lipid-Based Formulations.
Tanaka Y; Doi H; Katano T; Kasaoka S
Eur J Pharm Sci; 2021 Feb; 157():105604. PubMed ID: 33098990
[TBL] [Abstract][Full Text] [Related]
14. Rationale utilization of phospholipid excipients: a distinctive tool for progressing state of the art in research of emerging drug carriers.
Jebastin K; Narayanasamy D
J Liposome Res; 2023 Mar; 33(1):1-33. PubMed ID: 35543241
[TBL] [Abstract][Full Text] [Related]
15. Bioavailability of Celecoxib Formulated with Mesoporous Magnesium Carbonate-An In Vivo Evaluation.
Zardán Gómez de la Torre T; Lindmark T; Cheung O; Bergström C; Strømme M
Molecules; 2022 Sep; 27(19):. PubMed ID: 36234733
[TBL] [Abstract][Full Text] [Related]
16. Supersaturable diacyl phospholipid dispersion for improving oral bioavailability of brick dust molecule: A case study of Aprepitant.
Lale AS; Sirvi A; Debaje S; Patil S; Sangamwar AT
Eur J Pharm Biopharm; 2024 Apr; 197():114241. PubMed ID: 38432600
[TBL] [Abstract][Full Text] [Related]
17. Polymeric Precipitation Inhibitors Promote Fenofibrate Supersaturation and Enhance Drug Absorption from a Type IV Lipid-Based Formulation.
Suys EJA; Chalmers DK; Pouton CW; Porter CJH
Mol Pharm; 2018 Jun; 15(6):2355-2371. PubMed ID: 29659287
[TBL] [Abstract][Full Text] [Related]
18. Solubility enhancement of BCS Class II drug by solid phospholipid dispersions: Spray drying versus freeze-drying.
Fong SY; Ibisogly A; Bauer-Brandl A
Int J Pharm; 2015 Dec; 496(2):382-91. PubMed ID: 26468038
[TBL] [Abstract][Full Text] [Related]
19. The influence on the oral bioavailability of solubilized and suspended drug in a lipid nanoparticle formulation: In vitro and in vivo evaluation.
Elbrink K; Van Hees S; Roelant D; Loomans T; Holm R; Kiekens F
Eur J Pharm Biopharm; 2022 Oct; 179():1-10. PubMed ID: 36031014
[TBL] [Abstract][Full Text] [Related]
20. Correlating in Vitro Solubilization and Supersaturation Profiles with in Vivo Exposure for Lipid Based Formulations of the CETP Inhibitor CP-532,623.
McEvoy CL; Trevaskis NL; Feeney OM; Edwards GA; Perlman ME; Ambler CM; Porter CJH
Mol Pharm; 2017 Dec; 14(12):4525-4538. PubMed ID: 29076741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
